ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen To Buy KAI Pharma For $315 Million In Cash

DOW JONES NEWSWIRES Amgen Inc. (AMGN) has agreed to acquire privately held company KAI Pharmaceuticals for $315 million in cash, giving the drug maker rights to an experimental drug to treat chronic kidney disease. In connection with the deal, Amgen is providing a loan prior to closing for Phase 3 clinical testing of KAI-4169, a drug that is being studied for the treatment of secondary hyperparathyroidism, a common complication for patients who are on dialysis. The deal will give Amgen rights to KAI-4169, outside of Japan. "KAI has demonstrated encouraging results in the clinic. We are excited about acquiring KAI, as well as the opportunity to potentially deliver a novel therapy for chronic kidney disease patients on dialysis suffering from secondary hyperparathyroidism," said Sean E. Harper, executive vice president of research and development at Amgen. Amgen, the biggest stand-alone biotechnology company, has been making acquisitions in a bid to bolster its research-and-development pipeline as sales growth for older drugs has slowed. The transaction, which has been approved by KAI stockholders and both companies' boards, is subject to regulatory approvals. After the deal is completed, KAI will become a wholly owned unit of Amgen. Amgen shares closed at $67.02 on Monday and were inactive in premarket trading. The stock is up 4.4% so far this year. ---By Kristin Jones, Dow Jones Newswires; 212-416-2208; kristin.jones@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
03/28/201508:02:02Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
03/26/201521:09:30Portfolio Changes For The First Quarter Of 2015
03/26/201516:01:00Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From...
03/23/201520:21:07Amgen Is The Stock Of The Week
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201515:25:55Why ImmunoGen Inc. is Soaring Higher Today
03/23/201512:25:04Why ImmunoGen Inc. is Soaring Higher Today
03/23/201512:14:41Why ImmunoGen, Inc. is Soaring Higher Today
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/23/201509:00:00Amgen To Webcast Investor Call At the 73rd Annual Meeting of...
03/23/201507:30:40Biogen Idec shortens name; CEO says drug candidates in neurodegenerative...
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/21/201511:02:02Drug Spending Is Soaring: 3 Takeaways You Can't Miss
03/20/201509:00:00Amgen Submits Application For Investigational LDL Cholesterol-Lowering...
03/20/201507:56:19Court rejects Amgen's bid to block Neupogen biosimilar
03/20/201507:29:07The Market Has Got It Wrong - Cramer's Mad Money (3/19/15)
03/20/201506:42:59Does Esperion Have An Ace Up Its Sleeve?
03/19/201518:46:14Judge Denies Amgen's Request to Block Novartis's Biosimilar of...
03/19/201516:03:02Can This Biotech Stock Go from Good to Great?
03/18/201519:18:18How The Rushed Biosimilar Law Is Yielding Go-Slow Launches

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad